Mecasermin (INN) (trade name Increlex) is recombinant human insulin-like
growth factor 1 (IGF-I), which is used for the long-term treatment of growth failure
Easy to read patient leaflet for mecasermin. Includes indications, proper use,
special instructions, precautions, and possible side effects.
Increlex (mecasermin): For the treatment of growth failure due to Primary IGFD.
New approved drug details including side effects, uses and general information.
Jun 14, 2016 ... Find a comprehensive guide to possible side effects including common and rare
side effects when taking Increlex (Mecasermin [rDNA origin] ...
1.1 Severe Primary IGF-1 Deficiency (Primary IGFD) INCRELEX® (mecasermin [
rDNA origin] injection) is indicated for the treatment of: growth failure in .
INCRELEX (mecasermin) is recombinant human insulin-like growth factor-1 ...
Mecasermin was granted orphan status in the EU for “Treatment of growth ...
Aetna considers mecasermin (Increlex) and mecasermin rinfabate (Iplex)*
medically necessary for the treatment of growth failure in children with severe
Apr 1, 2015 ... Mecasermin injection is a man-made version of insulin-like growth factor-1 (IGF-1
) hormone. IGF-1 is produced in the liver and plays an ...
Mecasermin (Increlex®) is the recombinant DNA form of human insulin-like
growth factor-1 (rhIGF-1). In normal circulation, over 98% of rhIGF-1 is available
Medscape - Indication-specific dosing for Increlex (mecasermin), frequency-
based adverse effects, comprehensive interactions, contraindications, pregnancy